CM Mohan Yadav Breaks Ground for Haleon's Rs 2,000 Cr MP Plant
Synopsis
Madhya Pradesh Chief Minister Dr. Mohan Yadav on June 8, 2026 virtually broke ground for Haleon Group's first India manufacturing unit at Pithampur, backed by a Rs 2,000 crore investment promising 1,000 jobs and a 30 per cent women employment target.
Key Takeaways
Haleon Group will invest Rs 2,000 crore to set up its first manufacturing unit in India at Pithampur, Dhar district, Madhya Pradesh .
The ground-breaking ceremony was performed virtually by CM Dr.
Mohan Yadav from Bhopal Niwas on June 8, 2026 .
The facility is expected to create approximately 1,000 direct and indirect jobs .
The company has set a target of employing up to 30 per cent women in the new unit.
Madhya Pradesh is developing pharma clusters across Indore, Pithampur, Mandideep, Bhopal, Dewas , and Ujjain to support India's global pharma hub ambitions.
The investment aligns with the central government's PLI Scheme for Pharmaceuticals and the Make in India initiative.
Madhya Pradesh Chief Minister Dr. Mohan Yadav on Monday, June 8, 2026, virtually performed the ground-breaking ceremony for Haleon Group's first manufacturing unit in India, to be set up at Pithampur in Dhar district with an investment of Rs 2,000 crore. The ceremony was conducted from Bhopal Niwas, the Chief Minister's official residence.
Context
Announcing the development on X, Dr. Yadav said Madhya Pradesh is playing a major role in making India a 'Global Pharma Hub' — a global pharmaceutical hub. He noted that the Haleon unit at Pithampur will generate approximately 1,000 direct and indirect employment opportunities. The Chief Minister also highlighted the company's commitment to reserving up to 30 per cent of jobs for women, calling it a commendable initiative toward women's empowerment.
Haleon Group is a global consumer healthcare company that was spun off from GSK (GlaxoSmithKline). The Pithampur facility will mark the company's first dedicated manufacturing presence in India.
Policy Backdrop
The investment fits squarely within the framework of the Make in India initiative, launched in 2014, which identified pharmaceuticals as a priority sector for domestic manufacturing expansion. The Production Linked Incentive (PLI) Scheme for Pharmaceuticals, announced in 2021, further incentivised companies to set up or expand manufacturing capacity inside India.
Madhya Pradesh has been systematically developing dedicated pharma manufacturing clusters across Indore, Pithampur, Mandideep, Bhopal, Dewas, and Ujjain. Pithampur, already an established industrial zone near Indore, is emerging as the anchor cluster for large-scale pharmaceutical investment in the state.
Stakeholders and Impact
The most immediate beneficiaries are the estimated 1,000 workers — direct and indirect — who will find employment once the plant becomes operational. The 30 per cent women employment target, if achieved, would mean roughly 300 or more women joining the facility's workforce, adding a gender-equity dimension to an industrial investment.
For Dhar district and the broader Pithampur industrial belt, the Haleon unit adds to a growing cluster of pharmaceutical manufacturers, strengthening local supply chains and ancillary industries. State-level pharma cluster development also supports India's broader ambition of increasing its share of global generic medicine supply.
What's Next
The ground-breaking marks the start of construction; the commissioning timeline and actual employment ramp-up will be key milestones to watch. Dr. Yadav's government is also expected to push for further investments across the other five notified pharma clusters in the state. If Madhya Pradesh sustains this pace of investment attraction, it is positioned to become one of India's leading pharmaceutical manufacturing states alongside established hubs in Telangana, Gujarat, and Himachal Pradesh.
Point of View
A metric that eluded the state in earlier industrial policy cycles. By personally anchoring the virtual ceremony and publicly citing the women's employment target, Dr. Yadav is simultaneously pitching MP as an investor-friendly destination and reinforcing a social-equity narrative ahead of future elections. The investment also fits a broader competitive pattern among non-coastal states — MP, Rajasthan, Uttar Pradesh — racing to capture pharmaceutical FDI that has historically flowed to Telangana and Gujarat. Whether the 1,000-job promise and the 30 per cent women-hiring target translate into reality at commissioning will be the real test of the policy's credibility.
NationPress
2 Aug 2026
Frequently Asked Questions
Where is Haleon Group setting up its manufacturing unit in India?
Haleon Group is setting up its first manufacturing unit in India at Pithampur in Dhar district, Madhya Pradesh, with an investment of Rs 2,000 crore.
How many jobs will the Haleon Pithampur plant create?
The Haleon manufacturing unit at Pithampur is expected to create approximately 1,000 direct and indirect employment opportunities, with up to 30 per cent reserved for women.
What is Madhya Pradesh's role in India's pharma hub plan?
Madhya Pradesh is developing dedicated pharma manufacturing clusters in Indore, Pithampur, Mandideep, Bhopal, Dewas, and Ujjain to support India's goal of becoming a global pharmaceutical hub.
What is the Haleon Group?
Haleon Group is a global consumer healthcare company spun off from GSK. The Pithampur unit will be its first dedicated manufacturing facility in India.
What central government schemes support pharma investment in MP?
The Make in India initiative (2014) and the Production Linked Incentive (PLI) Scheme for Pharmaceuticals (2021) provide the national policy framework that supports investments like the Haleon plant in Madhya Pradesh.
